ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 03-08 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known	
Application Number	10/582,312
Filing Date	December 8, 2004 (Int'l)
First Named Inventor	Sergei O. BACHURIN
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	559592000200

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2001/0020028-A1	09-06-2001	Zefirov et al.	
	2.	US-2002/0102597-A1	08-01-2002	Bitler et al.	
	3.	US-2002/0115682-A1	08-22-2002	Zefirov et al.	
	4.	US-2002/0197233-A1	12-26-2002	Relton et al.	
	5.	US-2004/0044022-A1	03-04-2004	Zefirov, Jr. et al.	
	6.	US-2006/0140866-A1	06-29-2006	Zefirov et al.	
	7.	US-2007/0117834-A1	05-24-2007	Hung	
	8.	US-2007/0117835-A1	05-24-2007	Hung	
	9.	US-2007/0179174-A1	08-02-2007	Bachurin et al.	
	10.	US-3,718,657	02-27-1973	Garmaise et al.	
	11.	US-3,743,740	07-03-1973	Barkov et al.	
	12.	US-3,991,199	11-09-1976	Berger	
	13.	US-4,174,453	11-13-1979	Berger	
	14.	US-4,636,563	01-13-1987	Abou-Gharbia	
	15.	US-4,985,256	01-15-1991	Glick	
	16.	US-5,319,096-A	06-07-1994	Kosley Jr. et al.	
	17.	US-5,563,147-A	10-08-1996	Gilmore et al.	
	18.	US-5,958,919-A	09-28-1999	Olney et al.	
	19.	US-RE 36,397-E	10-16-1999	Zhang et al.	
	20.	US-6,017,957-A	01-25-2000	Skolnick et al.	
	21.	US-6,187,785-B1	02-13-2001	Zefirov et al.	
	22.	US-6,362,160-B1	03-26-2002	Dawson et al.	
	23.	US-6,391,871-B1	05-21-2002	Olney et al.	
	24.	US-6,930,112-B2	08-16-2005	Weaver et al.	
	25.	US-7,071,206-B2	07-04-2006	Zefirov et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	26.	CA-2,117,755-A1	10-11-1993	Schering Aktiengesellschaft		
	27.	DE-1 813 229	08-20-1970	Sumitomo Chemical Co. Ltd.	Translation of Abstract Only.	
	28.	DE-1 952 800	06-03-1971	Nautschno issledovatelskij institut farmakolgii i chimioterapii	Translation of Abstract Only.	

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 03-08 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	6

Complete if Known	
Application Number	10/582,312
Filing Date	December 8, 2004 (Int'l)
First Named Inventor	Sergei O. BACHURIN
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	559592000200

	29.	EP-0 230 370-A2, A3	07-29-1987	Merck Sharpe & Dohme Ltd.		
	30.	EP-0 424 179-A2, A3	04-24-1991	Olney		
	31.	EP-0 581 456-A1	02-02-1994	R.J. Reynolds Tobacco Company		
	32.	EP-0 876 818-A2, A3	11-11-1998	Zefirov et al.		
	33.	GB-1 245 155	09-08-1971	Sumitomo Chemical Company Limited		
	34.	GB-1 276 113	06-01-1972	Nauchno-Issledovatelsky Institut Farmakologií I Khmioterapii		
	35.	GB-1 450 002	09-22-1976	Endo Lab		
	36.	GB-1 586 655	03-25-1981	Pfizer		
	37.	JP-09-216882	08-19-1997	Isukura Sangyo KK	English language pages, pp. 38-156.	✓
	38.	RU-2 106 864-C1	03-20-1998	Zefirov et al.	Translation of Abstract Only.	
	39.	RU-2 140 417-C1	10-27-1999	Institute of Physiologically Active Substances of the Russian Academy of Sciences		✓
	40.	SU-592359-A	01-25-1978	Endo Laboratoris Inc.		
	41.	SU-665804-A	05-30-1979	Endo Laboratoris Inc.		
	42.	SU-873883-A	10-18-1981	Pfizer	Translation of Abstract Only.	
	43.	SU-1138164-A	02-07-1985	Vinogradova et al.		✓
	44.	SU-1442074-A3	11-30-1988	Amerikan Khoum Prodakts Korporeishn		
	45.	SU-1803108-A1	03-23-1993	Lugansk Medical Institute		✓
	46.	SU-1816451-A1	05-23-1993	Kharkov State Pharmaceutical Institute		✓
	47.	WO-93/20820-A1	10-28-1993	Schering Aktiengesellschaft		
	48.	WO-94/06428-A1	03-31-1994	The Children's Medical Center Corporation		
	49.	WO-97/15225-A1	05-01-1997	Zefirov et al.	Translation of Abstract Only.	

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 03-08 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,312
				Filing Date	December 8, 2004 (Int'l)
				First Named Inventor	Sergei O. BACHURIN
				Art Unit	1614
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	3	of	6	Attorney Docket Number	559592000200

	50.	WO-2005/055951-A2, A3	06-23-2005	Medivation, Inc.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	51.	ABOU-GHARBIA, M. et al. (July-December 1987). "Antipsychotic Activity of Substituted γ-Carbolines," *J. Med. Chem.* 30(7):1818-1823.	
	52.	ANONYMOUS. (1984). Table 78 *in* Early Diagnostics of Metabolic Diseases, Moscow, Russia, p. 304. (English Translation, 4 pages.)	
	53.	AVDULOV, N.A. et al. (1985). "Interaction of Psychotropic Preparations with Model Lipid Membranes," *Bull. Exp. Biol. Med.* 100(10):440-442. (English Translation, 4 pages.)	
	54.	BACHURIN, S. et al. (2001). "Neuroprotective and Cognition-enhancing Properties of MK-801 Flexible Analogs: Structure-Activity Relationships," *Ann. N.Y. Acad. Sci.* 939:219-236.	
	55.	BACHURIN, S.O. et al. (May 2003). "Mitochondria as a Target for Neurotoxins and Neuroprotective Agents," *Ann. N.Y. Acad. Sci.* 993:334-349.	
	56.	BAKER III, G.T. (January-April 1993). "Effects of Various Antioxidants on Aging in *Drosophila*," *Toxicol. Ind. Health* 9(1/2):163-186.	
	57.	BENES, L. (1986). "Free Radicals and Ischemic States," *Ceskoslovenska Farmacie* 35(5):230-232. (Translation of Abstract Only.)	
	58.	BENES, L. (June 1986). "Free Radicals and Ischemic States," *The Czechoslovak Pharmacy Journal* 35(5):230-232. (Alternative English Translation, 5 pages.)	
	59.	BUKATINA, Y.Y. et al. (1992). "Scale For Evaluating the Mental Condition of Elderly Dementia Patients," *Soc. Clin. Psychiatry* 2(4):29-37. (English Translation, 10 pgs.)	
	60.	BUU-HOÏ, N.P. et al. (1964). "Carcinogenic Nitrogen Compounds. Part XXXIX. A New Synthesis of γ-Carbolines and of 2,10-Diaza-anthracenes," *J. Chem. Soc.* 2:708-711.	
	61.	CATTANACH, C.J. et al. (1968). "Studies in the Indole Series. Part IV. Tetrahydro-1*H*-pyrido[4,3-*b*]-indoles as Serotonin Antagonists," *J. Chem. Soc.* C:1235-1243.	
	62.	COLLINGRIDGE, G.L. et al. (1994). The NMDA Receptor Second Edition, Oxford University Press: New York, NY, 4 pages (Table of Contents Only.)	
	63.	COMFORT, A. et al. (January 22, 1971). "Effect of Ethoxyquin on the Longevity of C3H Mice," *Nature* 229(5282):254-255.	
	64.	DISTERHOFT, J.F. et al. eds. (December 15, 1994). "Calcium Hypothesis of Aging and Dementia," *Ann. N.Y. Acad. Sci.* Vol.747, 4 pages. (Table of Contents Only.)	

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 03-08 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,312
				Filing Date	December 8, 2004 (Int'l)
				First Named Inventor	Sergei O. BACHURIN
				Art Unit	1614
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	4	of	6	Attorney Docket Number	559592000200

	65.	EVANS, R.H. et al. (January 1982). "The Effects of a Series of ω-Phosphonic α-Carboxylic Amino Acids on Electrically Evoked and Excitant Amino Acid-Induced Responses in Isolated Spinal Cord Preparations," *Brit. J. Pharmacol.* 75:65-75.	
	66.	FROLKIS, V.V. et al. (1991). Life Span Prolongation, Translated from Russian by Edelsburg, N.G., CRC Press: Boca Raton, FL, 9 pages. (Table of Contents Included.)	
	67.	GALENKO-YAROSHEVSKII, P.A. et al. (1996). "A Comparative Study of the Effects of Dimebon, Obsidan, Finoptin, and Cordaron on the Functional State of Ishcemic Focus and Size of Necrotic Zone in Experimental Myocardial Infarction," *Bull. Exp. Biol. Med.* 12:1205-1207, translated from (December 1996). *Byulliten' Experimental'noi Biologii I Meditsiny* 122(12):642-644.	
	68.	GANKINA, Y.M. et al. (1992). "Effect of Certain Antihistamine Preparations on ^{3}H-Mepyramine and ^{3}H-Cimetidine Binding to Histamine Receptors in the Rat Brain," *Chem. Pharm. J.* 26(5):9-12. (English Translation, 5 pages.)	
	69.	GANKINA, Y.M. et al. (1993). "Effect of Antihistamine Preparations on Labeled Mepyramine, Ketanserin, and Quinuclidinyl Benzilate Binding in the Rat Brain," *Exp. Clin. Pharmacol.* 56(1):22-24. (English Translation, 5 pages.)	
	70.	GEERTS, H. et al. (2003). "Galantamine Benefits in Alzheimer's Disease are Related to Increases in Dopamine Output," *Abstracts of the IX International Congress on Schizophrenia Research,* Colorado Springs, CO, March 29 - April 2, 2003, 60(1):135.	
	71.	GILL, R. et al. (1987). "High-Performance Liquid Chromatographic System for the Separation of Tricyclic Antidepressant and Related Drugs Using ODS-Hypersil," *J. Chromatogr.* 391(2):461-464.	
	72.	GRIGORYEV, V.V. et al. (1988). "Anticonvulsant Activity of Glutamate Receptor Antagonists in the Phosphorus-Containing Aminocarboxylic-Acid Series," *J. Chem. and Pharm.* 22(3):275-277. (English Translation, 3 pgs.)	
	73.	GRIGORYEV, V.V. (1993). "Effects of NMDA and Quinolinic Acid on Rat Cerebral Cortex Neurons," *Reports From the Academy of Sciences* 330(5):646-648. (English Translation, 4 pgs.)	
	74.	HARBERT, C.A. et al. (1980). "Neuroleptic Activity of the 5-Aryltetrahydro-γ-carboline Series," *Mol. Pharm.* 17:38-42.	
	75.	HELLER, W.M. et al. eds. (1989). USAN and the USP Dictionary of Drug Names: USAN 1990: 1961-1989 Cumulative List, U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 26th edition, p. 196.	
	76.	HÖRLEIN, U. (1954). "On Knowledge of the Tetrahydrocarboline Compounds (Communication I)," *Chem. Ber.* 87(4):463-472. (English Translation, 13 pgs.)	
	77.	HU, H.-L. et al. (2000). "Antioxidants May Contribute in the Fight Against Ageing: an in vitro Model," *Mech. Ageing Dev.* 121:217-230.	
	78.	International Preliminary Report on Patentability for PCT Application No. PCT/US2004/041081, issued on June 12, 2006, five pages.	
	79.	International Search Report mailed October 13, 2005, for PCT Patent Application No. PCT/US2004/041081 filed December 8, 2004, three pages.	
	80.	KITTOVÁ, M. et al. (November 1985). "Antiarrhythmic and Hemodynamic Effects of a Pyridoindole Derivative (DH 1011) on Experimental Models of Heart Rhythm and Function Disorders," *Bratisl lek. Listy.* 84(5):542-556. (English Translation, 15 pages.)	

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 03-08 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,312
				Filing Date	December 8, 2004 (Int'l)
				First Named Inventor	Sergei O. BACHURIN
				Art Unit	1614
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	5	of	6	Attorney Docket Number	559592000200

	81.	KLYUYEV, M.A. ed. (1991). Handbook: Medicinal Agents Used in Medical Practice in the USSR Meditsina Publishing House: Moscow, USSR, pg. 512. (English Translation, 2 pgs.)	
	82.	KOH, J-Y. et al. (1990). "β-Amyloid Protein Increases the Vulnerability of Cultured Cortical Neurons to Excitotoxic Damage," *Brain Res.* 533(2):315-320.	
	83.	KOST, A.N. et al. (1973). "Indole Chemistry: XXXIII. On NH Group Pyridylethylation in Indole Compounds," *Heterocyclic Compound Chemistry* 2:207-212. (English Translation, 6 pgs.)	
	84.	KUCHEROVA, N.F. et al. (1956). "Indole Derivatives. II. Synthesis of Certain 1,2,3,4-Tetrahydro-γ-Carboline Derivatives," *J. Gen. Chem.* 26(88):3149-3154. (English Translation, 6 pages.)	
	85.	KYSELOVA, Z. et al. (May 2003). "Pyridoindole Antioxidant Stobadine Protected Bovine Serum Albumin Against the Hydroxyl Radical Mediated Cross-linking *in Vitro*," *Arch. Gerontol. Geriatr.* 36(3):221-229.	
	86.	LAL, H. et al. eds. (1989). Excitatory Amino Acids and Drug Research , Alan R. Liss, Inc.: New York, NY, 17(4):380.	
	87.	LERMONTOVA, N.N. et al. (2001). "Dimebon and Tacrine Inhibit Neurotoxic Action of β-Amyloid in Culture and Block L-type Ca^{2+} Channels," *Bull. Exp. Biol. Med.* 132(11):1079-1083, translated from (November 2001). *Byulliten' Experimental'noi Biologii I Meditsiny* 132(11):545-550.	
	88.	LITCHFIELD, J.T. Jr. et al. (1949). "A Simplified Method of Evaluating Dose-Effect Experiments," *J. Pharmacol. Exp. Ther.* 96:99-113.	
	89.	MARAGOS, W.F. et al. (March 9, 1987). "Loss of Hippocampal [^{3}H]TCP Binding in Alzheimer's Disease," *Neurosci. Lett.* 74(3):371-376.	
	90.	MASHKOVSKIY, M.D. (1993). Drugs: A Manual for Physicians, Meditsina Publishing House: Moscow, USSR, 12th Edition, 1:383. (English Translation, 4 pages.)	
	91.	MATTSON, M.P. (January 1990). "Antigenic Changes Similar to Those Seen in Neurofibrillary Tangles are Elicited by Glutamate and Ca^{2+} Influx in Cultured Hippocampal Neurons," *Neuron* 2:105-117.	
	92.	MATTSON, M.P. et al. (February 1992). "β-Amyloid Peptides Destabilize Calcium Homeostasis and Render Human Cortical Neurons Vulnerable to Excitotoxicity," *J. Neurosci.* 12(2):376-389.	
	93.	MELKUMOVA, Y.R. (1994). "Antianginal and Antifibrillatory Properties of Dimebon," *Dissertation: Kuban State Medical Academy*, 170 pgs. (English Translation of Table of Contents and Section 5.1-5.4, 11 pages.)	
	94.	MILLS, L.R. et al. (January 1990). "Neuron-Specific and State-Specific Differences in Calcium Homeostatis Regulate the Generation and Degeneration of Neuronal Architecture," *Neuron* 2:149-163.	
	95.	MURRAY, A.M. et al. (1991). "Disturbances in Pre- and Postsynaptic Dopamine Systems in Parkinson's and Alzheimer's Disease," *Abstracts: Society for Neuroscience, 21st Annual Meeting of the Society for Neuroscience*, New Orleans, LA, November 10-15, 1991, 17(2):1260, Abstract No. 499.7.	
	96.	OBUKHOVA, L.K. (1975). "Chemical Geroprotectors and the Problem of Increasing Lifespan," *Uspekhi Khimii* 44:1914-1925. (English Translation, 19 pages.)	
	97.	OBUKHOVA, L.K. et al. (1984). "Molecular Mechanisms of Aging Retardation by Antioxidants," *Biological Problems of Aging* 4:44-80. (English Translation, 46 pages.)	

ALTERNATIVE TO PTO/SB/08A/B
(Based on PTO 03-08 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/582,312
				Filing Date	December 8, 2004 (Int'l)
				First Named Inventor	Sergei O. BACHURIN
				Art Unit	1614
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	6	of	6	Attorney Docket Number	559592000200

	98.	OXENKRUG, G. et al. (2001). "Antioxidant and Antiaging Activity of *N*-Acetylserotonin and Melatonin in the *in Vivo* Models," *Ann. N.Y. Acad. Sci.* 939:190-199.	
	99.	PRELLI, F. et al. (August 1988). "Differences Between Vascular and Plaque Core Amyloid in Alzheimer's Disease," *J. Neurochem.* 51(2):648-651.	
	100.	SAITOH, T. et al. (May 1991). "Protein Kinases and Phosphorylation in Neurologic Disorders and Cell Death," *Lab Invest.* 64(5):596-616.	
	101.	SHADURSKAYA, S.K. et al. (1986). "Neuromediator Mechanisms of the Effects of the Antihistamine Preparation Dimebon on the Brain," *Bull. Exp. Biol. Med.* S1(6):700-702. (English Translation, 4 pages.)	
	102.	SHEVSTOVA, E. et al. (March 2000). "*β*-Amyloid Peptide (25-35) as the Trigger of Mitochondrial Permeability Transition," *Second Colloquium on Mitochondria and Myopathies in Halle/Saale*, Halle-Wittenberg, Germany, March 31-April 2, 2000, one page.	
	103.	SHEVSTOVA, E. et al. (March 31, 2000). "Beta-Amyloid Peptide (25-35) as a Trigger of Mitochondrial Permeability Transition," *Eur. J. Med. Res.* 5(Suppl. 1):30.	
	104.	STOLC, S. et al. (1995). "Protective Effect of Stobadine, a Pyridoindole Antioxidant, in Hypoxia-Reoxygenation Injury of Ganglionic and Hippocampal Neurotransmission," *Mol. Chem. Neuropathol.* 25:199-212.	
	105.	Supplementary European Search Report mailed July 23, 2008, for Patent Application No. 04813405.0 filed December 8, 2004, three pages.	
	106.	TISHCHENKOVA, I.F. et al. (1991). "Detection of Dimebon in Biological Fluids and Tissue Homogenates Using the Thin-Layer Chromatography Densitometry Technique," *J. Chem. Pharm.* 25(11):78-79. (English Translation, 4 pgs.)	
	107.	VOLGER, B.W. (June 1991). "Alternatives in the Treatment of Memory Loss in Patients with Alzheimer's Disease," *Clin. Pharm.* 10(6):447-456.	
	108.	WELCH, W.M. et al. (October 1986). "Neuroleptics from the 4a,9b-*cis*- and 4a,9b-*trans*-2,3,4,4a,5,9b-Hexahydro-1*H*-pyrido[4,3-*b*]indole Series. 2," *J. Med. Chem.* 29(10):2093-2099.	
	109.	WOLFE, N. et al. (January 1988). "Neuropsychological Deficits Linked to Dopamine Deficiency in Alzheimer's Disease, Parkinson's Disease and Major Depression," *J. Clin. Exp. Neuropsychol.* 10(1):33.	
	110.	YAKHONTOV, L.N. et al. (1983). Synthetic Drugs, Natradze, A.G. ed., Meditsina Publishing House: Moscow, USSR, pp. 234-237 and Table of Contents (English Translation, 7 pages.)	
	111.	YANKNER, B.A. et al. (October 12, 1990). "Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides," *Science* 250(4978):279-282.	
	112.	YUROVSKAYA, M.A. et al. (1981). "Interaction of 1,2,3,4-Tetrahydro-γ-Carboline Iodomethylates with Nucleophilic Agents," *Heterocyclic Compound Chemistry* 8:1072-1078. (English Translation, 7 pgs.)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.